CARDURA XL Rx
Generic Name and Formulations:
Doxazosin (as mesylate) 4mg, 8mg; ext-rel tabs.
Indications for CARDURA XL:
Swallow whole. Take w. breakfast. Initially 4mg once daily; may titrate after 3–4 weeks to max 8mg/day. If therapy is stopped for several days, restart at 4mg once daily. Switching from Cardura to Cardura XL: initially 4mg once daily; do not take final evening dose of Cardura. Concomitant PDE-5 inhibitors: initiate at lowest dose.
Severe hepatic impairment: not recommended. Mild or moderate hepatic impairment. Syncope. Symptomatic hypotension. Exclude prostate cancer. Severe GI narrowing. Coronary insufficiency; discontinue if angina pectoris appears or worsen. Cataract surgery (intraoperative floppy iris syndrome possible). Elderly. Pregnancy, nursing mothers: not indicated for females.
Caution with strong CYP3A4 inhibitors (eg, atanazavir, clarithromycin, indinavir, ketoconazole, itraconazole, nefazodone, others). Additive hypotension with concomitant PDE-5 inhibitors.
Headache, dizziness, asthenia, hypotension, dyspnea, postural hypotension, somnolence, respiratory or urinary tract infections; rare: priapism.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Nicotinamide and Cancer
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML